Tom 1, Nr 4 (2023)
Artykuł przeglądowy
Opublikowany online: 2024-03-14
Potencjalna rola Helicobacter pylori i innych czynników dysbiozy jelitowej w rozwoju trądziku różowatego
1, 1, 1, 1
Dermatologia w Praktyce Klinicznej 2023;1(4):144-149.
Streszczenie
Trądzik różowaty jest przewlekłą chorobą zapalną, która objawia się rumieniem, teleangiektazjami, grudkami lub krostami. Mechanizm powstawania choroby wciąż nie został w pełni wyjaśniony. Wzrasta liczba badań i doniesień potwierdzających korzystny wpływ eradykacji Helicobacter pylori na przebieg choroby. Uznano, że bakteria ta prowadzi do aktywacji zapalnej odpowiedzi immunologicznej, co skutkuje indukcją objawów podobnych do trądziku różowatego. Inna teza sugeruje ścisły związek pomiędzy osią jelita–mózg–skóra, wpływającą na prawidłową mikroflorę i zdrowie jelit, a chorobami dermatologicznymi. Stwierdzono korelacje między trądzikiem różowatym a zwiększoną częstością występowania choroby Leśniowskiego–Crohna, wrzodziejącego zapalenia jelita grubego i zespołu jelita drażliwego.
Słowa kluczowe: trądzik różowatyHelicobacter pylorieradykacjamikrobiota
Referencje
- Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002; 46(4): 584–587.
- Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019; 80(6): 1722–1729.e7.
- Maruthappu T, Taylor M. Acne and rosacea in skin of colour. Clin Exp Dermatol. 2022; 47(2): 259–263.
- Yang X. Relationship between Helicobacter pylori and Rosacea: review and discussion. BMC Infect Dis. 2018; 18(1): 318.
- Wang FY, Chi CC. Rosacea, germs, and bowels: a review on gastrointestinal comorbidities and gut-skin axis of rosacea. Adv Ther. 2021; 38(3): 1415–1424.
- Searle T, Ali FR, Carolides S, et al. Rosacea and the gastrointestinal system. Australas J Dermatol. 2020; 61(4): 307–311.
- Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam Physician. 2015; 92(3): 187–196.
- Zip C. The role of skin care in optimizing treatment of acne and rosacea. Skin Therapy Lett. 2017; 22(3): 5–7.
- Katta R, Kramer MJo. Skin and diet: an update on the role of dietary change as a treatment strategy for skin disease. Skin Therapy Lett. 2018; 23(1): 1–5.
- Rivero AL, Whitfeld M. An update on the treatment of rosacea. Aust Prescr. 2018; 41(1): 20–24.
- FitzGerald R, Smith SM. An overview of helicobacter pylori infection. Methods Mol Biol. 2021; 2283: 1–14.
- Callaway E. Famous ancient iceman had familiar stomach infection. Nature. 2016.
- Guarneri C, Ceccarelli M, Rinaldi L, et al. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. Eur Rev Med Pharmacol Sci. 2020; 24(23): 12267–12287.
- de Brito BB, da Silva FA, Soares AS, et al. Pathogenesis and clinical management of gastric infection. World J Gastroenterol. 2019; 25(37): 5578–5589.
- Kunovsky L, Dite P, Jabandziev P, et al. infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. World J Gastrointest Oncol. 2021; 13(8): 835–844.
- AlBalbeesi A, Alsalman H, Alotaibi H, et al. Prevalence of helicobacter pylori infection among rosacea and chronic spontaneous urticaria patients in a tertiary hospital in Riyadh, Saudi Arabia. Cureus. 2021; 13(8): e17617.
- Kim HS. Microbiota in Rosacea. Am J Clin Dermatol. 2020; 21(Suppl 1): 25–35.
- Daniluk J. Helicobacter pylori eradication — the most common mistake. Lekarz POZ. 2021; 7(6): 411–420.
- Szlachcic A, Sliwowski Z, Karczewska E, et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol. 1999; 50(5): 777–786.
- Adriani A, Saracco GM, Pellicano R. Helicobacter pylori infection and dermatologic diseases: time to turn the page? G Ital Dermatol Venereol. 2020; 155(6): 709–710.
- Saleh P, Naghavi-Behzad M, Herizchi H, et al. Effects of Helicobacter pylori treatment on rosacea: A single-arm clinical trial study. J Dermatol. 2017; 44(9): 1033–1037.
- Authors, Responsible in representation of the DGVS:. S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol. 2017; 55(2): 167–206.
- Woo YuRi, Han YuJ, Kim HS, et al. Updates on the risk of neuropsychiatric and gastrointestinal comorbidities in rosacea and its possible relationship with the gut-brain-skin axis. Int J Mol Sci. 2020; 21(22).
- Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut-skin axis. Clin Dermatol. 2021; 39(5): 829–839.
- De Pessemier B, Grine L, Debaere M, et al. Gut-Skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021; 9(2).
- Tutka K, Żychowska M, Reich A. Diversity and composition of the skin, blood and gut microbiome in rosacea-a systematic review of the literature. Microorganisms. 2020; 8(11).
- Nam JH, Yun Y, Kim HS, et al. Rosacea and its association with enteral microbiota in Korean females. Exp Dermatol. 2018; 27(1): 37–42.
- Chen YJ, Lee WH, Ho HJ, et al. An altered fecal microbial profiling in rosacea patients compared to matched controls. J Formos Med Assoc. 2021; 120(1 Pt 1): 256–264.
- Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019; 118(7): 1083–1092.
- Weimers P, Munkholm P. The natural history of IBD: lessons learned. Curr Treat Options Gastroenterol. 2018; 16(1): 101–111.
- Daou H, Paradiso M, Hennessy K, et al. Rosacea and the microbiome: a systematic review. Dermatol Ther (Heidelb). 2021; 11(1): 1–12.
- Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017; 176(1): 100–106.
- Kim M, Choi KH, Hwang SeW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. J Am Acad Dermatol. 2017; 76(1): 40–48.
- Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021; 160(5): 1486–1501.
- Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep. 2016; 18(2): 8.
- Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6): 492–506.
- Maarouf M, Platto JF, Shi VY. The role of nutrition in inflammatory pilosebaceous disorders: Implication of the skin-gut axis. Australas J Dermatol. 2019; 60(2): e90–e98.
- Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008; 6(7): 759–764.
- Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. Gastroenterology. 2016 [Epub ahead of print].
- Spiegel B. Gravity and the gut: a hypothesis of irritable bowel syndrome. Am J Gastroenterol. 2022; 117(12): 1933–1947.
- Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17(4): 349–359.